在深南的心力衰竭患者中使用补充和替代医学
Deborah Ejem1, Kwaku Duah Oppong2, Zehra Gok Metin3
1From the School of Nursing, University of Alabama at Birmingham, Birmingham.
Southern medical journal
|July 15, 2025
概括
19.6%的心力衰竭患者报告使用补充和替代医学 (CAM),其中草药和食补充剂是最常见的. 需要进一步研究CAM在心力衰竭中的安全性和有效性.
科学领域:
- 心脏病学 心脏病学
- 综合医学是一个整体的医学.
- 公共卫生 公共卫生
背景情况:
- 心力衰竭 (HF) 管理已经进步,但患者经常探索补充和替代医学 (CAM) 改善生活质量和未满足需求.
- 患有HF的息护理患者经常寻求CAM来解决身体和情绪症状.
- 了解HF中CAM利用模式对于综合护理至关重要.
研究的目的:
- 确定心力衰竭患者中CAM使用的流行率和模式.
- 探索使用的CAM类型和在这个人群中使用的原因.
- 为了确定与CAM在门诊HF患者的使用相关的人口特征.
主要方法:
- 在一个学术医疗门诊HF诊所进行了一项横截面描述性研究.
- 数据采集使用来自国家健康访谈调查和堪萨斯城心肌病问卷的CAM相关问题.
- 使用SPSS分析了社会人口统计变量和描述性统计数据.
主要成果:
- 在250名高频参与者中,19.6%报告使用CAM,平均年龄为65岁.
- 草药产品和食补充剂是最常见的CAM形式 (57%).
- 缓解疼痛和整体健康是CAM使用的主要原因;没有发现任何重要的社会人口预测因素.
结论:
- 在这个HF队列中,CAM的患病率低于其他群体.
- 草药产品和食补充剂是HF患者经常使用的CAM模式.
- 建议进一步研究CAM的安全性和有效性,特别是补充剂,在HF中.
相关概念视频
Heart Failure VI: Adjunct Therapies
31
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
31
Heart Failure V: Medical Management
27
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
27
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
513
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
513
Heart Failure VII: Nursing Interventions
142
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
142
Heart Failure Drugs: β-Blockers
435
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
435
Heart Failure Drugs: Inotropic Agents
733
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
733


